Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Viktor V Chirikov, Chris Walker, Jennifer M Stephens, Patricia Schepman, Richard Chambers, Mahmoud Bakir, Gregory W Poorman, Seema Haider & Mohammed Farghaly. (2021) Evaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial. ClinicoEconomics and Outcomes Research 13, pages 409-420.
Read now
Read now
Articles from other publishers (14)
Parnnaphat Luksameesate, Aree Tanavalee, Surachat Ngorsuraches & Suthira Taychakhoonavudh. (2023) Using a discrete choice experiment to elicit patients’ preferences and willingness-to-pay for knee osteoarthritis treatments in Thailand. Scientific Reports 13:1.
Crossref
Crossref
Parnnaphat Luksameesate, Aree Tanavalee & Suthira Taychakhoonavudh. (2022) An economic evaluation of knee osteoarthritis treatments in Thailand. Frontiers in Pharmacology 13.
Crossref
Crossref
Jiayu Shi, Kenan Fan, Lei Yan, Zijuan Fan, Fei Li, Guishan Wang, Haifeng Liu, Peidong Liu, Hongmei Yu, Jiao Jiao Li & Bin Wang. (2022) Cost Effectiveness of Pharmacological Management for Osteoarthritis: A Systematic Review. Applied Health Economics and Health Policy 20:3, pages 351-370.
Crossref
Crossref
Xueshan Sun, Xuemei Zhen, Xiaoqian Hu, Yuanyuan Li, ShuYan Gu, Yuxuan Gu, Zixuan Zhao, Wei Yang & Hengjin Dong. (2021) Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis. Cost Effectiveness and Resource Allocation 19:1.
Crossref
Crossref
Ting Zhao, Hasnat Ahmad, Barbara Graaff, Qing Xia, Tania Winzenberg, Dawn Aitken & Andrew J. Palmer. (2021) Systematic Review of the Evolution of Health‐Economic Evaluation Models of Osteoarthritis. Arthritis Care & Research 73:11, pages 1617-1627.
Crossref
Crossref
M.V. Bielsa-Fernández, J.L. Tamayo-de la Cuesta, J. Lizárraga-López, J.M. Remes-Troche, R. Carmona-Sánchez, J.M. Aldana-Ledesma, J.M. Avendaño-Reyes, M.A. Ballesteros-Amozorrutia, M. De Ariño, L. de Giau-Triulzi, R. Flores-Rendón, H. Huerta-Guerrero, J.A. González-González, A. Hernández-Guerrero, E. Murcio-Pérez, J. Jáquez-Quintana, A. Meixueiro-Daza, J.R. Nogueira-de Rojas, H. Rodríguez-Hernández, R. Santoyo-Valenzuela, S.C. Solorzano-Olmos, L.F. Uscanga-Domínguez & F. Zamarripa-Dorsey. (2020) The Mexican consensus on the diagnosis, treatment, and prevention of NSAID-induced gastropathy and enteropathy. Revista de Gastroenterología de México (English Edition) 85:2, pages 190-206.
Crossref
Crossref
M.V. Bielsa-Fernández, J.L. Tamayo-de la Cuesta, J. Lizárraga-López, J.M. Remes-Troche, R. Carmona-Sánchez, J.M. Aldana-Ledesma, J.M. Avendaño-Reyes, M.A. Ballesteros-Amozorrutia, M. De Ariño, L. de Giau-Triulzi, R. Flores-Rendón, H. Huerta-Guerrero, J.A. González-González, A. Hernández-Guerrero, E. Murcio-Pérez, J.O. Jáquez-Quintana, A. Meixueiro-Daza, J.R. Nogueira-de Rojas, H. Rodríguez-Hernández, R. Santoyo-Valenzuela, S.C. Solorzano-Olmos, L.F. Uscanga-Domínguez & F. Zamarripa-Dorsey. (2020) Consenso mexicano sobre diagnóstico, prevención y tratamiento de la gastropatía y enteropatía por antiinflamatorios no esteroideos. Revista de Gastroenterología de México 85:2, pages 190-206.
Crossref
Crossref
Sherif A Nasef, A. Aziz Shaaban, Joaquin Mould-Quevedo & Tarek A Ismail. (2015) The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia. Health Economics Review 5:1.
Crossref
Crossref
Carmelo Scarpignato, Angel Lanas, Corrado Blandizzi, Willem F Lems, Matthias Hermann & Richard H Hunt. (2015) Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Medicine 13:1.
Crossref
Crossref
Mickaël Hiligsmann, Cyrus Cooper, Nigel Arden, Maarten Boers, Jaime C. Branco, Maria Luisa Brandi, Olivier Bruyère, Francis Guillemin, Marc C. Hochberg, David J. Hunter, John A. Kanis, Tore K. Kvien, Andrea Laslop, Jean-Pierre Pelletier, Daniel Pinto, Susanne Reiter-Niesert, René Rizzoli, Lucio C. Rovati, Johan L. (Hans) Severens, Stuart Silverman, Yannis Tsouderos, Peter Tugwell & Jean-Yves Reginster. (2013) Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism 43:3, pages 303-313.
Crossref
Crossref
Ronald C. Wielage, Julie A. Myers, Robert W. Klein & Michael Happich. (2013) Cost-Effectiveness Analyses of Osteoarthritis Oral Therapies: a Systematic Review. Applied Health Economics and Health Policy 11:6, pages 593-618.
Crossref
Crossref
Nadir Hammoumraoui, Sid Ahmed Kherraf, Joaquin Mould-Quevedo & Tarek A. Ismail. (2013) The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria. Journal of Health Economics and Outcomes Research 1:2, pages 184-199.
Crossref
Crossref
Ronald C. Wielage, Megha Bansal, J. Scott Andrews, Robert W. Klein & Michael Happich. (2013) Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective. Applied Health Economics and Health Policy 11:3, pages 219-236.
Crossref
Crossref
Feng Xie, Pimwara Tanvejsilp, Kaitryn Campbell & Kathryn Gaebel. (2013) Cost-Effectiveness of Pharmaceutical Management for Osteoarthritis Pain. Drugs & Aging 30:5, pages 277-284.
Crossref
Crossref